Caveolin-1 temporal modulation enhances antibody drug efficacy in heterogeneous gastric cancer

Resistance mechanisms and heterogeneity in HER2-positive gastric cancers (GC) limit Trastuzumab benefit in 32% of patients, and other targeted therapies have failed in clinical trials. Using patient samples, patient-derived xenografts (PDXs), partially humanized biological models, and HER2-targeted...

Descripción completa

Detalles Bibliográficos
Autores principales: Pereira, Patrícia M. R., Mandleywala, Komal, Monette, Sébastien, Lumish, Melissa, Tully, Kathryn M., Panikar, Sandeep Surendra, Cornejo, Mike, Mauguen, Audrey, Ragupathi, Ashwin, Keltee, Nai C., Mattar, Marissa, Janjigian, Yelena Y., Lewis, Jason S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9085816/
https://www.ncbi.nlm.nih.gov/pubmed/35534471
http://dx.doi.org/10.1038/s41467-022-30142-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9085816/
https://www.ncbi.nlm.nih.gov/pubmed/35534471
http://dx.doi.org/10.1038/s41467-022-30142-9

Ejemplares similares